市场调查报告书
商品编码
1335881
数位剂量吸入器的全球市场规模、份额和行业趋势分析报告:按产品(计量吸入器(MDI)、干粉吸入器(DPI))、按类型、按适应症(慢性阻塞性肺病、气喘等)、地区预测,2023-2030Global Digital Dose Inhaler Market Size, Share & Industry Trends Analysis Report By Product (Metered Dose Inhaler (MDI), and Dry Powder Inhaler (DPI)), By Type, By Indication (COPD, Asthma, and Others), By Regional Outlook and Forecast, 2023 - 2030 |
预计到 2030 年,数位剂量吸入器市场规模将达到 490 亿美元,预测期内年复合成长率为 19.6%。
此外,为感染者提供护理的医疗用品的需求也在增加。呼吸支援设备,如雾化器、制氧机、维生器和监视器是初级保健中最常用的医疗设备。 COVID-19大流行的持续爆发对医疗设备产业产生了积极影响。它影响了数位剂量吸入市场。然而,这种流行病的蔓延影响了供应链并减少了对数位剂量吸入设备的需求,导致许多地区的工业暂时停工和政府宣布封锁。
此外,由于对患者资料安全性的担忧,市场扩张预计将缓慢。由于缺乏对慢性阻塞性肺病和气喘症状的了解,大多数患有呼吸道疾病的人未能得到诊断,因此接受了不正确的治疗。这可能是由于患者缺乏技术熟悉度和支付限製造成的。鑑于目前的情况,有限的设备可用性也是一个问题,将对预测期内的数位剂量吸入器市场产生负面影响。
产品展望
根据产品,市场分为计量吸入器(MDI)和干粉吸入器(DPI)。 2022年,计量吸入器(MDI)领域占市场最高收入份额。这是由于医疗费用上涨和呼吸系统疾病患者数量增加。此外,与吸入药物开拓相关的持续技术进步,药物动力学/药效学(PK/PD)建模和以小剂量输送高剂量药物的基于奈米技术的製剂,提高了药物的治疗效果.增加和影响整个市场的关键要素。
按类型分類的展望
按类型划分,市场分为品牌药和仿製药。仿製药领域在市场上占有最高的收入份额。数位吸入器通常包括感测器和连接装置,用于监控和追踪药物使用。数位吸入器可以记录吸入器使用的日期、时间和频率,为患者、医疗保健提供者和研究人员提供有价值的资讯。一些数位吸入器可以透过药物提醒和警报进行编程。
指标展望
根据迹象,市场分为气喘、慢性阻塞性肺病(COPD)等。 2022年,慢性阻塞性肺病(COPD)细分市场占据主导地位。由于全球慢性阻塞性肺病罹患率上升,预计该细分市场将在预测期内占据主导地位。烟草使用、空气污染、花粉、化学蒸气和儿童感染疾病都会导致慢性阻塞性肺病。数位剂量吸入器可以帮助慢性阻塞性肺病患者监测他们的呼吸健康和药物依从性,使他们能够更有效地管理他们的疾病。
区域展望
按地区划分,对北美、欧洲、亚太地区和拉丁美洲地区市场进行了分析。 2022年,北美地区以最高的收入份额引领市场。这是由于密集的研究和开发工作以及对目前可用高科技呼吸器的认识的提高。此外,儿童和老年人呼吸道疾病盛行率的增加将推动预测期内市场的扩张。
The Global Digital Dose Inhaler Market size is expected to reach $49 billion by 2030, rising at a market growth of 19.6% CAGR during the forecast period.
Cigarette smoking and long-term exposure to other respiratory contaminants are typically the cause of various diseases, including asthma. The asthma segment will capture more than 30% share of the market by 2030. The World Health Organization (WHO) estimates that annually, tobacco kills more than eight million people. 7 million deaths are due to direct tobacco use, while approximately 1.2 million are due to latent or secondhand smoking. Cigarette smoking is one of the most prevalent forms of tobacco use worldwide. Over 80% of the 1.3 billion tobacco consumers reside in low- and middle-income countries, where mortality and illness due to tobacco use are prevalent. Some of the factors impacting the market are globally increasing air pollution, developing technological advances and concerns related to patient data security.
Automobiles, forest fires, household combustion, and industrial facilities are widely recognized sources of air pollution. Particulate matter, ozone, carbon monoxide, sulfur dioxide, and nitrogen are the pollutants of most threat to public health. Both indoor and external air pollution contribute significantly to mortality and morbidity by causing respiratory and other diseases. According to the World Health Organization, nearly all the world's population consumes air with elevated levels of pollutants exceeding WHO guidelines. Low- and middle-income countries are the most vulnerable to these threats. Additionally, the increasing adoption of AI and IoT has been identified as one of the most significant market trends. AI technology analyzes intricate medical data using algorithms and software, reducing the need for direct human input. This will aid in decreasing the likelihood of human error, reducing treatment costs, and enhancing healthcare outcomes. Therefore, Long-term exposure to ambient air contaminants is associated with an increase in the incidence of respiratory diseases and the increasing incorporation of AI and the adoption of IoT will improve the treatment of asthma and COPD, thereby increasing demand.
Furthermore, in order to provide care for the infected population, there is a growing demand for medical supplies. Respiratory support devices like atomizers, oxygen generators, life-support machines, and monitors are some of the most frequently utilized medical devices in primary medical care. The continuous outbreak of the COVID-19 pandemic had a positive effect on the medical device industry. It affects the market for digital dose inhalation. However, this escalating pandemic affects the supply chain and reduces demand for digital dose inhalation devices, resulting in the temporary shutdown of industries and the announcement of lockdowns by governments in numerous regions.
Additionally, due to concerns about patient data security, it is predicted that the market will expand slowly. Due to a lack of knowledge of the symptoms of COPD and asthma, the vast majority of individuals with respiratory illnesses go undiagnosed and are consequently given the incorrect treatment. This may be a result of patients not being technologically savvy and the payment restrictions. The device's limited availability is another issue that, given the existing circumstance, will have a negative impact on the market for digital dosage inhalers throughout the projection period.
Product Outlook
Based on Product, the market is segmented into metered dose inhaler (MDI) and dry powder inhaler (DPI). In 2022, the metered dose inhaler (MDI) segment held the highest revenue share in the market. This is due to rising healthcare costs and increased respiratory disease cases. Furthermore, consistent technological advancements related to the development of inhalation medication, like mechanistic Pharmacokinetic/Pharmacodynamics (PK/PD) modeling, and nanotechnology-based formulations with high drug loads delivered in smaller dose sizes, are some of the critical factors involved in enhancing the therapeutic efficacy of the medication and influencing the overall market.
Type Outlook
On the basis of type, the market is fragmented into branded medication and generic medication. The generic medication segment garnered the highest revenue share in the market. Frequently, digital inhalers include sensors and connectivity features that monitor and track medication usage. They can log the date, time, and frequency of inhaler use, providing valuable information to patients, healthcare providers, and researchers. A few digital inhalers can be programmed with medication reminders and alerts.
Indication Outlook
By indication, the market is bifurcated into asthma, chronic obstructive pulmonary disease (COPD), and others. In 2022, the chronic obstructive pulmonary disease (COPD) segment dominated the market. The segment is anticipated to dominate over the forecast period due to the global increase in COPD incidence. Tobacco use, air pollution, pollen, chemical vapors, and childhood infections are all causes of COPD. Digital Dose Inhalers aid COPD patients in monitoring their respiratory health and drug adherence, enabling them to manage their illness more effectively.
Regional Outlook
Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. In 2022, the North America region led the market by generating the highest revenue share. This is due to rigorous research and development efforts, as well as an increased awareness of the high-tech respiratory devices currently available. In addition, an increase in the prevalence of respiratory conditions among children and older people will drive market expansion over the forecast period.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Sensirion AG, Teva Pharmaceuticals Industries Ltd., OPKO Health, Inc., Propeller Health (ResMed, Inc.), Novartis AG, AstraZeneca PLC, Glenmark Pharmaceuticals Limited, Beximco Pharmaceuticals Ltd., GlaxoSmithKline PLC and Mundipharma Deutschland GmbH & Co. KG.
Strategies Deployed in Digital Dose Inhaler Market
Jun-2023: Teva Pharmaceutical signed an agreement with Phil, Inc., a patient access platform company. Under this agreement, both companies would make Digihaler products available for prescription utilizing the PhilRx Patient Access Platform. The Digihaler system offered by Teva is a smart inhaler that delivers objective inhaler data to support doctors and patients in asthma management.
Jan-2023: AstraZeneca received FDA approval for Airsupra, a pressurized metered-dose inhaler. The approval in the US is for the as-required treatment or prevention of bronchoconstriction and to decrease the risk of exacerbations in people suffering from Asthma of 18 years or more.
Jun-2022: Glenmark Pharm announced the launch of Indament, a novel fixed-dose combination (FDC) drug. The launched drug would be available in three forms with a fixed dose of Indacaterol 150 mcg and variable doses of Mometasone 80 mcg, 160 mcg and 320 mcg to be taken once daily.
Apr-2022: GlaxoSmithKline Pharmaceuticals rolled out Trelegy Ellipta, the first once-daily single-inhaler triple therapy, for Chronic Obstructive Pulmonary Disease patients. The product is used as a maintenance treatment to avert and relieve symptoms related to Chronic Obstructive Pulmonary Disease for patients of age 18 and above.
Sep-2020: Teva Respiratory, LLC., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., introduced AirDuo Digihaler inhalation powder and ArmonAir Digihaler inhalation powder, the digital maintenance inhalers for patients with asthma. The AirDuo Digiinhaler is utilized to manage symptoms of wheezing in patients and asthma. The ArmonAir Digihaler for the treatment of asthma in patients.
Jul-2020: Teva Respiratory, LLC., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. released ProAir Digihaler Inhalation Powder, the digital rescue inhaler indicated in patients of four years and above. The product is used for the prevention and treatment of bronchospasm who have reversible obstructive airway disease.
Jul-2020: Novartis received approval from European commision for Enerzair® Breezhaler®, including the sensor and app. The Product offers inhalation confirmation, medication reminders, and access to objective data to better help therapeutic decisions.
May-2020: Glenmark Pharmaceuticals Ltd. introduced AIRZ-FF, a Single Inhaler Triple Therapy. The launched product is for Chronic Obstructive Pulmonary Disease with the combination of two bronchodilators, Glycopyrronium & Formoterol, and the inhalation corticosteroid Fluticasone propionate. Furthermore, the AIRZ-FF decreases the risk of Severe attacks and eliminates dependence on multiple inhalers.
May-2020: Propeller Health came into partnership with AstraZeneca, a global pharmaceutical company. This partnership would offer respiratory patients a tool to help control their condition and enhance their medication adherence, a key factor in keeping people out of the hospital. Moreover, Propeller Health got FDA approval for a sensor and app to be used with AstraZeneca's Symbicort inhaler for asthma and COPD.
Market Segments covered in the Report:
By Product
By Type
By Indication
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures